Table 1 Patient demographics

Stem type

 Primary stem

38 (51%)

16 (40%)

22 (63%)

 Revision stem

37 (49%)

24 (60%)

13 (37%)

Age (years)

79.3 ± 9.8 (32–96)

80.6 ± 6.2 (67–96)

77.8 ± 12.7 (32–96)

Sex

 Female

42 (56%)

24 (60%)

18 (51%)

 Male

33 (44%)

16 (40%)

17 (49%)

Body mass index

24.1 ± 4.7 (16.4–40.3)

23.9 ± 3.9 (18.1–33.7)

24.3 ± 5.4 (16.4–40.3)

ASA^a

 1

2 (3%)

0

2 (6%)

 2

45 (60.0%)

23 (57.5%)

22 (63%)

 3

28 (37%)

17 (42.5%)

11 (31%)

Charlson comorbidity index

 2

3 (4%)

0

3 (9%)

 3

6 (8%)

5 (13%)

1 (3%)

 4

19 (25%)

12 (30%)

7 (20%)

 5+

47 (63%)

23 (57%)

24 (68%)

Bone mineral density, T-score

−3.1 ± 0.5 (−2.4- -3.8)

−3.0 ± 0.7 (−2.4- -3.8)

−3.1 ± 0.6 (−2.5 - -3.7)

Interval between index procedure and hip arthroplasty (months)

3 (IQR:9)

(1–87)

1(IQR:1)

(1–3)

7(IQR:4)

(4–87)

 Cephalomedullary nail

24 (32%)

13 (33%)

11 (31%)

 Plate

51 (68%)

27 (67%)

24 (69%)

Failure of index procedure

 Lag screw cut-out

48 (64%)

31 (78%)

17 (49%)

 Implant breakage or fracture collapse

22 (29%)

9 (22%)

13 (37%)

 Avascular necrosis

5 (7%)

0

5 (14%)

Hip arthroplasty procedure

 Bipolar hemiarthroplasty

62 (83%)

31 (78%)

31 (89%)

 Total hip arthroplasty

13 (17%)

9 (22%)

4 (11%)

Surgery duration (mins)

117.4 ± 48.6 (60–300)

118.3 ± 43.1 (60–240)

116.3 ± 54.9 (60–300)

Intraoperative blood loss (ml)

587.5 ± 399.2 (100–1500)

664.3 ± 298.2 (300–1000)

555.9 ± 438.4 (100–1500)

Length of stay (days)

7(IQR: 4) (2–94)

8(IQR:6) (2–94)

7(IQR:3) (2–19)

Follow-up duration (months)

116.2 ± 61.9 (13–234)

120.1 ± 59.4 (13–229)

111.2 ± 65.3 (22–234)

Mortality rate (one-year mortality)

8 (11%)

5 (13%)

3 (9%)